Monopar Therapeutics Inc. (MNPR), a clinical-stage radiopharma company, is scheduled to present additional data from its phase I imaging and dosimetry clinical trial of imaging agent MNPR-101-Zr at the upcoming European Association of Nuclear Medicine 2024 Annual Congress to be held in Hamburg, Germany on October 19-23, 2024.
MNPR-101-Zr is a zirconium-89 (imaging radioisotope) labeled version of MNPR-101, the company's proprietary first-in-class humanized monoclonal antibody. MNPR-101 targets the urokinase plasminogen activator receptor (uPAR), which is expressed in numerous tumor types including pancreatic, breast, colorectal, and bladder.
For comments and feedback contact: editorial@rttnews.com
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.